69839-83-4Relevant articles and documents
Inhibitors of the FEZ-1 metallo-β-lactamase
Lienard, Benoit M.R.,Horsfall, Louise E.,Galleni, Moreno,Frere, Jean-Marie,Schofield, Christopher J.
, p. 964 - 968 (2008/12/23)
Metallo-β-lactamases (MBLs) catalyze the hydrolysis of β-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a Ki of 6.1 ± 0.7 μM against the FEZ-1 MBL but does not significantly inhibit the IMP-1, BcII, CphA or L1 MBLs.
Method of treating hemoglobinopathies
-
, (2008/06/13)
A therapeutic process for treating anemias in primates, including man, particularly those anemias of genetic origin including sickle-cell anemia, which comprises administering to an anemic primate an amount of a polyhydroxy benzoic, mandelic or phenylacetic acid derivative as specified at a dose level sufficient to increase fetal hemoglobin.
Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors
-
, (2008/06/13)
Di and trihydroxybenzohydroxamic acids, amides, alkyl substituted amides and phenyl esters, ribonucleotide reductase inhibitors.